ALT's end-of-phase 2 meeting with the FDA provided a clear clinical plan for pemvidutide, but the phase 3 program will require 5,000 patients. ALT's $139M in cash is enough to stay afloat for a while ...
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Altimmune ( (ALT)) just unveiled an ...
Accelerating DX of shareholder meetings at listed companies using generative AI to provide total support for IR strategies The concept behind smartQA was devised by eA, which boasts over 20 years of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results